دورية
Clinical Manifestations of Human T Lymphotropic Virus Type I-Infected Patients with Systemic Lupus Erythematosus
| العنوان: | Clinical Manifestations of Human T Lymphotropic Virus Type I-Infected Patients with Systemic Lupus Erythematosus |
|---|---|
| المؤلفون: | Akimoto, Masaki, Matsushita, Kakushi, Suruga, Yukio, Aoki, Noriko, Ozaki, Atsuo, Uozumi, Kimiharu, Tei, Chuwa, Arima, Naomichi |
| المصدر: | Journal of Rheumatology; September 2007, Vol. 34 Issue: 9 p1841-1848, 8p |
| مستخلص: | OBJECTIVE: Human T lymphotropic virus type I (HTLV-I) may be associated with some connective tissue autoimmune diseases, including systemic lupus erythematosus (SLE). To determine the relationship between HTLV-I infection and SLE, we examined the clinical manifestations of SLE patients with HTLV-I infection. METHODS: Eighty-nine patients with SLE were screened for antibodies to HTLV-I by electrochemiluminescence immunoassay. The presence of HTLV-I proviral sequences in peripheral blood mononuclear cells (PBMC) was determined by real-time polymerase chain reaction (PCR) quantification and Southern blotting analysis. The differences in clinical manifestations between HTLV-I-seropositive and seronegative patients with SLE were analyzed statistically. RESULTS: Fourteen of 89 (15.7%) patients were HTLV-I seropositive. All PBMC samples from 11 patients tested by PCR and 3 samples from 10 patients tested by Southern blotting analysis were positive for HTLV-I-related sequences. The age of HTLV-I-seropositive patients with SLE was significantly higher than that of seronegative patients (median 60 vs 42 yrs; p < 0.0005). The age at onset of SLE in HTLV-I-seropositive patients was also significantly higher than that of seronegative patients (median 45.5 vs 30 yrs; p <0.0005). The lymphocyte count in HTLV-I-seropositive SLE patients was significantly higher than that of seronegative patients (median 1740 vs 1066/µl; p = 0.027). The maintenance dose of prednisolone in HTLV-I-seropositive patients with SLE was significantly lower than that in seronegative patients (median 5 vs 9 mg/day; p = 0.012). CONCLUSION: This is the first report of the differences in clinical manifestations between SLE patients with and without HTLV-I infection. Our results suggest some involvement of HTLV-I in the pathogenesis of SLE. |
| قاعدة البيانات: | Supplemental Index |
| تدمد: | 0315162X 14992752 |
|---|